Letters High cost of new drugs

Regulatory agencies should engage in drug pricing

BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4524 (Published 23 August 2016) Cite this as: BMJ 2016;354:i4524
  1. Raffaella Ravinetto, senior scientist1,
  2. Gianluca Gaidano, professor2
  1. 1Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium
  2. 2Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
  1. rravinetto{at}itg.be

Mazzucato argues that drug pricing policies “must be completely transparent, so that governments can negotiate for better value on behalf of their populations.”1 She also observes that the US government never exercised its right to cap prices of drugs developed through publicly funded research.2 In Europe, the European Medicines …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe